PP
MYGN icon

PDT Partners’s Myriad Genetics MYGN Stock Holding History

PDT Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41,405
Closed -$220K – 675
2025
Q2 		$220K Sell
41,405
-55,029
-57% -$325K 0.01% 629
2025
Q1 		$855K Buy
+96,434
New +$1.16M 0.06% 415
2021
Q2 		– Sell
-11,760
Closed -$358K – 910
2021
Q1 		$358K Sell
11,760
-52,714
-82% -$1.5M 0.03% 572
2020
Q4 		$1.27M Sell
64,474
-60,975
-49% -$985K 0.09% 284
2020
Q3 		$1.64M Buy
+125,449
New +$1.59M 0.11% 239
2017
Q3 		– Sell
-328,200
Closed -$8.48M – 547
2017
Q2 		$8.48M Buy
+328,200
New +$6.97M 0.34% 106
2017
Q1 		– Sell
-222,056
Closed -$3.7M – 514
2016
Q4 		$3.7M Buy
222,056
+51,556
+30% +$933K 0.24% 175
2016
Q3 		$3.51M Buy
170,500
+31,000
+22% +$786K 0.21% 173
2016
Q2 		$4.27M Hold
139,500
– – 0.34% 136
2016
Q1 		$5.22M Buy
139,500
+59,300
+74% +$2.23M 0.33% 120
2015
Q4 		$3.46M Buy
80,200
+7,886
+11% +$333K 0.47% 80
2015
Q3 		$2.71M Buy
72,314
+23,672
+49% +$840K 0.06% 350
2015
Q2 		$1.65M Buy
+48,642
New +$1.65M 0.04% 505
2014
Q4 		– Sell
-28,214
Closed -$1.09M – 925
2014
Q3 		$1.09M Sell
28,214
-3,428
-11% -$128K 0.03% 610
2014
Q2 		$1.23M Sell
31,642
-2,914
-8% -$108K 0.03% 623
2014
Q1 		$1.18M Buy
+34,556
New +$1.07M 0.03% 625
2013
Q4 		– Sell
-430,743
Closed -$10.1M – 985
2013
Q3 		$10.1M Buy
430,743
+260,370
+153% +$7.4M 0.27% 66
2013
Q2 		$4.58M Buy
+170,373
New +$4.94M 0.11% 223

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PDT Partners's MYGN Position: Q3 2025 in Review

PDT Partners sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 41,405 shares — an estimated $220K sold.

PDT Partners first reported a position in MYGN in Q2 2013 and held it in 18 quarters. The position peaked at $10.1M in Q3 2013. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • PDT Partners reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • PDT Partners sold 41,405 Myriad Genetics shares in Q3 2025, an estimated $220K.
  • PDT Partners first reported a position in Myriad Genetics in Q2 2013 and held it in 18 quarters.
  • PDT Partners's Myriad Genetics position peaked at $10.1M in Q3 2013.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on PDT Partners's 13F filing for Q3 2025, filed 17 Nov 2025.